MDCLF (Medincell) 1-Year Share Buyback Ratio: -8.60% (As of Mar. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDCLF Medincell SA MDCLF
77 GF Score
Price $34.39
GF Value $27.51
! 5 Warning Signs
View Full Analysis

What is Medincell 1-Year Share Buyback Ratio?

Medincell MDCLF +393.00% 77 1-Year Share Buyback Ratio is -8.60 as of Mar. 2026. GuruFocus rates MDCLF with a GF Score™ of 77/100 and a GF Value™ of $27.51. The stock has 5 warning signs investors should review. Among 1,108 Biotechnology companies, Medincell ranks better than 58.21% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Medincell's current 1-Year Share Buyback Ratio was -8.60%.

MDCLF's 1-Year Share Buyback Ratio is ranked better than
58.21% of 1108 companies
in the Biotechnology industry
Industry Median: -13.6 vs MDCLF: -8.60

Medincell  (OTCPK:MDCLF) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Medincell 1-Year Share Buyback Ratio Related Terms

MDCLF vs VRTX, REGN, ALNY: 1-Year Share Buyback Ratio Comparison

For the Biotechnology subindustry, Medincell's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medincell 1-Year Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medincell's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Medincell's 1-Year Share Buyback Ratio falls into.


MDCLF
77GF Score
Medincell SA MDCLF
1-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell 1-Year Share Buyback Ratio Calculation

Medincell's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Mar. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Mar. 2025 )
=(33.066 - 35.907) / 33.066
=-8.6%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 1-Year Share Buyback Ratio of -8.60 mean?
Medincell (MDCLF) has a 1-Year Share Buyback Ratio of -8.60 as of Mar. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Medincell and its competitors. According to the industry distribution chart, Medincell ranks #463 out of 1108 companies in the Biotechnology industry, placing it in the top 41.8%.
Is Medincell's 1-Year Share Buyback Ratio too high?
Medincell's current 1-Year Share Buyback Ratio is -8.60. Based on the distribution chart, Medincell ranks #463 out of 1108 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Medincell has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Medincell's 1-Year Share Buyback Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medincell ranks #463 out of 1108 companies for 1-Year Share Buyback Ratio. This puts Medincell in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Medincell and its competitors. Medincell's current 1-Year Share Buyback Ratio is -8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Medincell (MDCLF) has a current 1-Year Share Buyback Ratio of -8.60. The stock's GF Value™ is $27.51, compared to a current price of $34.39 — trading 25% above its estimated fair value. The current 1-Year Share Buyback Ratio is -8.60. Medincell's overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Medincell (MDCLF), the current 1-Year Share Buyback Ratio is -8.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (MDCLF) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of $34.39 is trading 25% above its estimated GF Value™ of $27.51.

Key valuation signals for MDCLF:

  • 1-Year Share Buyback Ratio: -8.60
  • GF Value™: $27.51 vs. price of $34.39 (25% above fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the MDCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
77GF Score

Get the complete analysis for MDCLF

1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$34.39
Price
$27.51
GF Value